Published in Epigenomics on February 01, 2010
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors | NCT03366116
Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol (2012) 1.23
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res (2015) 1.15
Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia (2012) 1.05
Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma. Oncotarget (2014) 0.94
Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure. PLoS Genet (2013) 0.86
New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer. Clin Cancer Res (2014) 0.81
Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. Oncol Lett (2015) 0.81
DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells. PLoS One (2014) 0.81
Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. J Urol (2011) 0.80
Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol (2016) 0.79
A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Oncotarget (2015) 0.78
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. Mol Pharm (2015) 0.76
TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma. Mol Cancer (2015) 0.76
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. Cancer Res (2015) 0.76
Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget (2016) 0.75
Epigenetics in cancer stem cells. Mol Cancer (2017) 0.75
5-aza-2'-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells. Oncotarget (2016) 0.75
Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res (2007) 4.89
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns. Hum Mol Genet (2009) 2.85
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. Int J Epidemiol (2010) 2.34
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16. Mol Cell (2008) 1.99
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res (2007) 1.65
Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer (2009) 1.64
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma (2012) 1.57
Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res (2007) 1.33
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol (2009) 1.29
Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol (2007) 1.09
Rapid and quantitative method of allele-specific DNA methylation analysis. Biotechniques (2006) 1.08
Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res (2010) 1.06
Lack of increases in methylation at three CpG-rich genomic loci in non-mitotic adult tissues during aging. BMC Med Genet (2007) 1.04
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol (2012) 0.91
2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett (2008) 0.88
Mono-allelic retrotransposon insertion addresses epigenetic transcriptional repression in human genome. J Biomed Sci (2012) 0.87
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer (2014) 0.85
Evaluating new treatment options for MDS. Clin Adv Hematol Oncol (2007) 0.80
Incorporation of zebularine from its 2'-deoxyribonucleoside triphosphate derivative and activity as a template-coding nucleobase. Nucleosides Nucleotides Nucleic Acids (2008) 0.78
Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol (2009) 0.76
A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics (2010) 0.76
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. Br J Haematol (2014) 0.76
Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients. Oncol Lett (2010) 0.75